Vigil Neuroscience study for Alzheimer’s drug to proceed with FDA restrictions (VIGL)
Iryna Drozd Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate ...
Iryna Drozd Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate ...
Michael Vi/iStock Editorial via Getty Images Developers of a drug class called anti-TIGIT immunotherapies traded higher in pre-market trading on ...
By Darryl Cornelius, Las Vegas Friday, Aug. 4, 2023 | 2 a.m. An increasingly popular drug has been flying under ...
KUALA LUMPUR: Singapore hanged a third prisoner in two weeks on Thursday for drug trafficking despite calls for the city-state ...
A team of scientists from Harvard Medical School has identified a combination of drugs that can reverse the aging process ...
Zorica Nastasic Introduction I give a hold rating to Kala Pharmaceuticals (NASDAQ:KALA). I think the company has an exciting product ...
The trainee police officers are part of a network of law enforcement specialists in Thailand, but also across the region, ...
JHVEPhotoSo far, 2023 is turning out to be a great year for the market. As of this writing, the S&P ...
In the dot-com days, everyone launched a website and became a “dot com company.” Today’s equivalent is peppering your investor ...
jetcityimage While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) will likely rule the obesity drug market for the next decade, ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.